Emerging Antibiotic Resistance Patterns Affect Visual Outcome Treating Acute Endophthalmitis.
antibiotic resistance
corticosteroids
endophthalmitis
moxifloxacin
vancomycin
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
23 Jun 2022
23 Jun 2022
Historique:
received:
25
04
2022
revised:
08
06
2022
accepted:
10
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Background: Examining the effect of antibiotic resistance, use of intravitreal antibiotics and systemic corticosteroids on visual outcome of eyes with acute endophthalmitis. Methods: We included 226 eyes with acute endophthalmitis, treated using a standardized protocol. Visual outcome up to 12 months was assessed related to biopsy results, antibiotics resistance and treatment regimens. Results: Vitreous biopsies were more likely to be culture-positive (41.1%) than anterior chamber biopsies (21.6%, p < 0.0001). Antibiotic resistance for amikacin was found in 19 eyes (24.7%), vancomycin in 29 eyes (31.5%) and moxiflocacin in 14 eyes (16.1%). At presentation 91.53% of eyes had BCVA < 20/40, reducing by 1 month to 69.94% (p < 0.0001) and remaining stable at 12 months. There was no difference in visual outcome for those receiving early systemic corticosteroids. Endophthalmitis following cataract surgery (OR 1.66, 1.04−2.66 95% CI, p = 0.03) and receiving intravitreal vancomycin (OR 3.15, 1.18−8.42 95% CI, p = 0.02) were associated with a greater chance of final BCVA ≥ 20/40. Conclusion: Using vitreous taps with intravitreal antibiotics, despite an increase in resistance to both vancomycin and moxifloxacin, results in a final BCVA > 20/200 in half of eyes and ≥20/40 in a third. Early treatment with intravitreal antibiotics should not be delayed.
Identifiants
pubmed: 35884097
pii: antibiotics11070843
doi: 10.3390/antibiotics11070843
pmc: PMC9311540
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mediators Inflamm. 2012;2012:196094
pubmed: 22973073
Surv Ophthalmol. 2018 Sep - Oct;63(5):677-693
pubmed: 29453989
Acta Ophthalmol. 2012 Nov;90(7):e572-3
pubmed: 22429465
J Ophthalmic Inflamm Infect. 2020 Feb 27;10(1):9
pubmed: 32103368
Curr Opin Ophthalmol. 2021 Jan;32(1):62-68
pubmed: 33196543
Ophthalmol Retina. 2018 Sep;2(9):979-980
pubmed: 31047231
Arch Ophthalmol. 1995 Dec;113(12):1479-96
pubmed: 7487614
Surv Ophthalmol. 1997 Mar-Apr;41(5):395-401
pubmed: 9163836
Ophthalmology. 2020 Feb;127(2):151-158
pubmed: 31611015
Br J Ophthalmol. 2016 Apr;100(4):446-52
pubmed: 26701686
Clin Exp Ophthalmol. 2020 Aug;48(6):813-820
pubmed: 32348002
Arch Ophthalmol. 2006 Feb;124(2):178-82
pubmed: 16476886
Surv Ophthalmol. 1998 Nov-Dec;43(3):193-224
pubmed: 9862309
Int Ophthalmol. 2020 Jan;40(1):73-79
pubmed: 31414274
J Glob Antimicrob Resist. 2022 Jun;29:236-240
pubmed: 35339737
Ophthalmol Retina. 2020 Nov;4(11):1103-1108
pubmed: 32387316
J Cataract Refract Surg. 2008 Sep;34(9):1439-50
pubmed: 18721702
JAMA Ophthalmol. 2017 Jul 1;135(7):814-815
pubmed: 28617914
J Ophthalmic Inflamm Infect. 2013 Apr 22;3(1):46
pubmed: 23607574
Retina. 2008 Mar;28(3):473-6
pubmed: 18327141
Am J Ophthalmol Case Rep. 2018 Dec 08;13:127-130
pubmed: 30662972
Br J Ophthalmol. 2007 Oct;91(10):1350-3
pubmed: 17389745
Ophthalmology. 2018 Aug;125(8):1279-1286
pubmed: 29477689
Int J Retina Vitreous. 2021 Feb 16;7(1):14
pubmed: 33593443
Am J Ophthalmol. 2007 Feb;143(2):338-40
pubmed: 17258525
Ophthalmology. 2005 Jul;112(7):1199-206
pubmed: 15921759
Ophthalmology. 2014 Dec;121(12):2387-92
pubmed: 25178807
Am J Ophthalmol Case Rep. 2018 Feb 28;10:211-214
pubmed: 29552670
Clin Microbiol Infect. 2015 Jun;21(6):592.e1-8
pubmed: 25680315